Two more patients die as Juno’s lead CAR-T turns lethal again; trial halted
Juno’s lead CAR-T drug is killing more patients, and this time it may have reached the end of the clinical road.
Four months after the biotech was forced to scramble to save the program in the wake of three patient deaths, Juno says that two more patients have died of cerebral edema out of only 12 more patients treated in the study.
Juno has voluntarily put the study back on clinical hold and informed regulators at the FDA, who may not be so quick to allow this study to resume this time around.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
